Impact of age and vector construct on striatal and nigral transgene expression

Nicole K Polinski1,2, Fredric P Manfredsson1,3, Matthew J Benskey1, D Luke Fischer1, Christopher J Kemp1, Kathy Steece-Collier1,3, Ivette M Sandoval1, Katrina L Paumier1 and Caryl E Sortwell1,3

Therapeutic protein delivery using viral vectors has shown promise in preclinical models of Parkinson’s disease (PD) but clinical trial success remains elusive. This may partially be due to a failure to include advanced age as a covariate despite aging being the primary risk factor for PD. We investigated transgene expression following intracerebral injections of recombinant adeno-associated virus pseudotypes 2/2 (rAAV2/2), 2/5 (rAAV2/5), 2/9 (rAAV2/9), and lentivirus (LV) expressing green fluorescent protein (GFP) in aged versus young adult rats. Both rAAV2/2 and rAAV2/5 yielded lower GFP expression following injection to either the aged substantia nigra or striatum. rAAV2/9-mediated GFP expression was deficient in the aged striatonigral system but displayed identical transgene expression between ages in the nigrostriatal system. Young and aged rats displayed equivalent GFP levels following LV injection to the striatonigral system but LV-delivered GFP was deficient in delivering GFP to the aged nigrostriatal system. Notably, age-related transgene expression deficiencies revealed by protein quantitation were poorly predicted by GFP-immunoreactive cell counts. Further, in situ hybridization for the viral C3A promoter revealed surprisingly limited tropism for astrocytes compared to neurons. Our results demonstrate that aging is a critical covariate to consider when designing gene therapy approaches for PD.

Molecular Therapy — Methods & Clinical Development (2016) 3, 16082; doi:10.1038/mtm.2016.82; published online 7 December 2016

INTRODUCTION

Viral vectors are useful tools to deliver genes to the central nervous system (CNS), allowing stable expression of an exogenous protein, short hairpin RNA, or other genomic material. The benefits of viral vectors include site-specific expression, delivery of transgenes to dividing and nondividing cells, stable transgene expression, and targeted tropism.1–2 These benefits, along with an improved safety profile, have led to the use of viral vector-mediated gene therapy to treat diseases of the difficult-to-target CNS or to generate animal models of CNS disorders.1–8 In particular, gene therapy is currently being explored in clinical trials for Alzheimer’s disease (AD)1,4 and Parkinson’s disease (PD)1,3—two diseases in which there are no disease-modifying treatments and symptomatic treatments only provide a moderate benefit.9–11 Multiple clinical trials have completed phase 1 safety testing for viral vector-mediated gene therapy in PD.1,2 Unfortunately, the early phase 2 efficacy trials have not shown improvement beyond the placebo effect or above levels currently achieved with symptomatic treatments.1,2 While limitations in the predictive validity of PD models likely impact translation of gene therapy to the clinic, consideration should also be given to the fact that preclinical studies almost exclusively use young adult animals.12–18 Age is the single greatest risk factor for developing PD and previous results demonstrate that age can dramatically influence therapeutic efficacy in PD models.19,20 In the case of trophic factor gene therapy for PD, it is likely that transgene expression must reach a critical threshold in order to be therapeutically effective. Understanding the impact of age on viral vector transduction efficiency is required for the design of successful gene therapy for PD.

The two most common vector classes used for delivery of genes to the CNS are recombinant adeno-associated virus (rAAV) and lentivirus (LV).1,3,5–7,21 The transduction properties of these recombinant vector classes have been extensively characterized in the CNS of young adult animals, with both resulting in stable transduction that can last years after injection.1,2,22–24 Limited evidence suggests that the age of the transduced subject can negatively impact the efficiency of certain rAAV pseudotypes. For example, aged rat septal neurons have been shown to be relatively resistant to transduction mediated by rAAV2/2.25 Further, we have documented a robust deficiency in rAAV2/S-mediated transduction of the substantia nigra pars compacta (SNpc) in aged as compared to young adult rats.2,26 Taken together, this limited evidence suggests certain vectors may not perform as efficiently in the aged brain.

To directly address this concern, the present study compared the ability of three rAAV and one LV vector to deliver transgene to the young adult (3 months) and aged (20 months) rat brain. The constructs chosen were rAAV2/2, rAAV2/5, rAAV2/9, and LV pseudotyped with vesicular stomatitis virus (VSV-G) due to previous reports of transduction changes25,26—or lack thereof27—with
Reduced transgene expression in aged striatum and substantia nigra
NR Polinski et al.

age and relevance to PD preclinical and clinical trials.1,12–17,25–27 The respective viral vectors, expressing a green fluorescent protein (GFP) transgene, were unilaterally injected into either the SNpc to transduce the nigrostriatal system or into the striatum to transduce the striatonigral system. The striatum is the structure most often targeted in PD gene therapy clinical trials.1,3,12–17,25–27 Transgene expression was assessed by quantifying GFP immuno reactive cells, GFP protein levels in anterograde structures, as well as GFP mRNA expression via qPCR and in situ hybridization. Since the ultimate goal of trophic factor gene therapy is protein delivery, we designated Western blot measures of GFP protein expression in anterograde structures as the primary outcome measure. Using this criterion, our results show a significant decrease in transgene expression in the aged nigrostriatal system using rAAV2/2, rAAV2/5, and LV, but not rAAV2/9. In contrast, in the aged striatonigral system, rAAV2/2, rAAV2/5, and rAAV2/9 express lower transgene levels with age whereas LV is equally as efficient between ages. Our results demonstrate that advanced age impacts the efficiency of viral vectors, with most—but not all—viral vectors impaired in the aged versus young adult rat brain.

RESULTS

Previous reports have found transduction deficiencies in the aged rat following injection of rAAV2/2 in the septum, rAAV2/5 in the SN, but not with rAAV2/9 in the SN.25–27 However, systematic comparison of the impact of age and brain region on viral vector transduction efficiency is lacking. In order to validate and expand previous findings, we sought to investigate the generalizability of this age-related deficiency to various vector constructs and an additional brain structure by systematically characterizing the changes in transduction efficiency with age. To accomplish this, we injected rAAV2/2, rAAV2/5, rAAV2/9, or LV expressing GFP driven by the chicken beta actin/cytomegalovirus enhancer (CBA/CMV) promoter hybrid into the SNpc to target the nigrostriatal system, or into the striatum to target the striatonigral system (Supplementary Figure S1). At 1 month postinjection, when transgene expression levels asymptote,22 we assessed transduction efficiency at the injection site with immunohistochemical or RNA measures, as well as transgene expression in the anterograde structure (septum following SNpc injection, or SN pars reticulata (SNpr) following striatal injection) using Western blotting for GFP to measure system-specific transduction. To preclude signal resulting from retrograde transport of the viral vectors, special care was taken with SNpr samples to avoid inclusion of SNpc tissue in the microdissection (Supplementary Figure S2). In addition, to ensure any changes in GFP expression with age were not due to age-related neuronal loss or vector-related toxicity, we quantified the number of tyrosine hydroxylase immuno reactive (TH+) neurons in the SNpc of young adult and aged rats. No significant difference was found for either age or vector injection for rAAV2/2 GFP (age: F (1,16) = 2.90, P = 0.149; injection: F (1,16) = 0.421, P = 0.545; Supplementary Figure S3a), rAAV2/9 GFP (age: F (1,16) = 0.029, P = 0.868; injection: F (1,16) = 1.98, P = 0.185; Supplementary Figure S3b), rAAV2/5 GFP (age: F (1,11) = 4.63, P = 0.054; injection: F (1,11) = 0.63, P = 0.444; Supplementary Figure S3c), or LV GFP (age: F (1,12) = 0.05, P = 0.833; injection: F (1,12) = 0.81, P = 0.398; Supplementary Figure S3d), as has been reported previously.26–29

Experiment 1. Vector transgene expression levels in the nigrostriatal system and midbrain following intranigral injections to the young adult and aged rat

Age-related decreases in exogenous GFP protein in the nigrostriatal system are observed with rAAV2/2, rAAV2/5, and LV, but not rAAV2/9 intranigral injections. To investigate transgene expression in the nigrostriatal system, we quantified GFP protein in the anterograde striatal structure at one month postinjection into the SNpc. This approach allowed us to avoid inclusion of GFP protein within nondopaminergic neurons in the SN and ventral mesencephalon that also are transduced following SNpc vector injections.26–30,31 GFP protein level was our primary outcome measure to assess transgene delivery due to the fact that adequate protein expression is the primary determinant of functional and neuroanatomical benefits of viral vector-mediated gene therapy.13 Aged rats displayed significantly lower levels of GFP in the striatum as compared to young adult rats following injection with three of the four vector constructs (Figure 1). Aged rat striatal tissue contained 62% less GFP following rAAV2/2 GFP transduction (P = 0.005; Figure 1a), 75% less GFP following rAAV2/5 GFP transduction (P = 0.043; Figure 1c), and 57% less GFP following LV GFP transduction (P = 0.016; Figure 1d) as compared to their young adult rat counterparts. The sole viral vector that did not display decreased levels of transgene expression in the aged rat was rAAV2/9, which conversely, trended toward an increase in striatal GFP levels in the aged compared to young adult rat (P = 0.087; Figure 1b). These results demonstrate that advanced age presents a barrier to efficient transduction with many, but not all, of the viral vector constructs tested in the rat nigrostriatal system.

Age-related decreases in exogenous protein expression in the nigrostriatal system are not reflected by differences in total GFP-positive cells within the mesencephalon. To assess the relationship between the number of transduced cells in the mesencephalon and transduction efficiency in the nigrostriatal system, we first quantified the total number of GFP-positive (GFP+) cells throughout the midbrain with unbiased stereology. No significant differences were observed in total numbers of GFP+ cells in the midbrain following rAAV2/2 GFP (P = 0.135; Figure 2a), rAAV2/5 GFP (P = 0.141; Figure 2g), and LV GFP (P = 0.307; Figure 2i) injection into the aged as compared to young adult rat SNpc. However, following rAAV2/9 GFP injection into the SNpc, aged rats exhibited greater numbers of GFP+ cells in the midbrain as compared to young adult rats (P = 0.037; Figure 2d). To determine whether aging impacted the phenotype of cells expressing GFP, we quantified the ratio of GFP+ neurons to GFP+ glia (microglia and astrocytes). No differences were seen between ages in the percent of neurons, astrocytes, or microglia expressing GFP for any vector construct (Supplementary Figure S4a). The overwhelming majority (>98% for rAAV pseudotypes and >85% for LV) of GFP+ cells were neuronal following injection in the SNpc (Supplementary Figure S4; Supplementary Table S1). These results demonstrate that age-related decreases in transgene protein expression in the nigrostriatal system (Figure 1) are not readily detectable using total counts of GFP+ cells in the mesencephalon.

Quantification of GFP+/TH+ SNpc neurons reveals fewer GFP+ nigrostriatal dopamine neurons in aged rats injected with rAAV2/2 GFP and LV GFP. To investigate the number of transduced SNpc neurons specifically, we performed dual immunofluorescent labeling for GFP and TH (Figure 2b,e,h,k). rAAV2/2 GFP and LV GFP displayed a 47% (P = 0.022) and 35% (P = 0.025) reduction, respectively, in the number of nigrostriatal SNpc dopaminergic neurons expressing GFP in the aged brain as compared to the young adult rat brain (Figure 2b–c and Figure 2k–l). No significant differences in the number of nigrostriatal dopaminergic neurons expressing GFP were observed between ages following rAAV2/5 GFP (P = 0.356; Figure 2h–i) or rAAV2/9 GFP (P = 0.184; Figure 2e–f). The fact that decreases in striatal GFP levels in aged rats following intranigral injections (Figure 1) are associated
with decreased GFP+/TH+ SNpc neurons in some (rAAV2/2, LV) but not all (rAAV2/5) vector constructs suggests that the dual labeling GFP/TH approach can be somewhat predictive of the impact of aging on vector-mediated transgene expression in the nigrostriatal system.

Age-related decreases in GFP mRNA are observed following intranigral injection with rAAV2/2, rAAV2/5, and LV, but not rAAV2/9. To investigate whether age-related changes in GFP protein expression are due to deficiencies in steps of transduction upstream of protein synthesis, we used the complimentary approaches of qPCR and RNAscope in situ hybridization. qPCR was not conducted on the rAAV2/5 and LV SNpc due to lack of tissue availability. qPCR analyses of SNpc tissue from young adult and aged rats injected with rAAV2/2 GFP revealed a trend towards an age-related decrease in GFP mRNA, with the aged rat SNpc containing fivefold lower levels of GFP mRNA than the young adult SNpc (P = 0.109; Supplementary Figure S5c). In contrast, the SNpc of rats injected with rAAV2/9 contained equal levels of GFP mRNA between young adult and aged rats (P = 0.723; Supplementary Figure S5d). RNAscope in situ hybridization for GFP mRNA in the midbrain revealed a similar pattern, with decreased GFP mRNA puncta in the aged as compared to young adult rat following intranigral rAAV2/2 GFP injection, but not rAAV2/9 GFP injection (Supplementary Figure S5a,b). Decreased GFP mRNA in aged rats was also observed in RNAscope in situ hybridization with rAAV2/5 and LV (Supplementary Figures S5e,f), following the trends observed with rAAV2/2 (Supplementary Figure S5a,c) and a previous report demonstrating decreased GFP mRNA in

Figure 1  Viral vector-mediated expression of GFP is reduced in the aged nigrostriatal system with rAAV2/2, rAAV2/5, and LV, but not rAAV2/9. Representative Western blot and quantitation of GFP in striatal samples of young adult (Young) and aged (Aged) rats one month post-injection with (a) rAAV2/2 GFP, (b) rAAV2/9 GFP, (c) rAAV2/5 GFP, or (d) LV GFP. (a) Aged (n = 4) rats expressed significantly less striatal GFP than young adult (n = 5) rats following rAAV2/2 GFP transduction (P ≤ 0.01). (b) Young adult (n = 8) and aged (n = 7) rats expressed equivalent levels of GFP following rAAV2/9 GFP transduction (P > 0.05). (c) Aged (n = 3) rats expressed significantly less GFP than young adult (n = 10) rats following rAAV2/5 GFP transduction (P ≤ 0.05). (d) Aged (n = 4) rats expressed significantly less striatal GFP than young adult (n = 6) rats following LV GFP transduction (P ≤ 0.05). Values are expressed as the percent of the young mean optical density scores, with GFP signal normalized to tubulin controls ± SEM for each group. GFP, green fluorescent protein; LV, lentivirus; rAAV, recombinant adeno-associated virus; SEM, standard error of the mean.
the aged ventral mesencephalon following transduction with rAAV2/5. Together, these results suggest that levels of GFP mRNA are also decreased in cases where viral vectors display an age-related decrease in nigrostriatal transduction as assessed by GFP protein levels.

Experiment 2. Vector transgene expression levels in the striatonigral system and striatum following intrastriatal injections to the young adult and aged rat

Age-related decreases in exogenous GFP protein in the striatonigral system are observed following intrastriatal rAAV2/2, rAAV2/5, and rAAV2/9, but not LV injections. Similar to our assessment of the nigrostriatal system, the ability of intrastriatal vector injections to deliver exogenous GFP to the anterograde SNpr was measured by protein analyses in SNpr tissue (Supplementary Figures S1 and S2). Striatal injection of viral vectors expressing tropic factors are used to simultaneously provide exogenous protein to dopaminergic nigrostriatal terminals through local transgene expression and tropic factor secretion, and anterogradely deliver protein to the SN via the striatonigral pathway. Aged rats displayed significantly lower levels of GFP protein as compared to young adult rats following injection with three of the four vector constructs (Figure 3). Similar to results following intranigral injections, rAAV2/2 displayed a 67% reduction in GFP expression ($P = 0.001$; Figure 3a) and rAAV2/5 displayed a 58% reduction in GFP expression ($P = 0.023$; Figure 3c) in the aged as compared to the young adult SNpr. However, unlike results with rAAV2/9, which displayed no age-related decrease in GFP protein expression following intranigral injections, following intrastriatal injections rAAV2/9 GFP expression was reduced by 55% in the aged SNpr as compared to the young adult rat ($P = 0.001$; Figure 3b). In contrast, LV GFP was the sole viral vector resistant to the age-related decrease in transgene expression in the striatonigral system ($P = 0.402$; Figure 3d) despite displaying a deficiency in GFP expression in the aged as compared to young adult rat nigrostriatal system (Figure 1d). These results indicate that the aged rat striatonigral system is, in general, also relatively resistant to viral vector transduction when compared to the young adult rat. However, age-related decreases in transgene expression are unique to specific viral vectors and cannot be generalized across brain structures.

Age-related changes in striatonigral expression of GFP are not detectable by quantitation of GFP+ cells in the striatum. To assess the relationship between the number of transduced cells in the striatum and transgene expression in the striatonigral pathway, we quantified the total number of GFP+ cells within the striatum using unbiased stereology. No significant differences were observed in total numbers of striatal GFP+ cells following rAAV2/2 GFP ($P = 0.448$; Figure 4a), rAAV2/9 GFP ($P = 0.506$; Figure 4d), rAAV2/5 GFP ($P = 0.096$; Figure 4g), or LV GFP ($P = 0.762$; Figure 4j) injection into the aged versus young adult rat. As observed when we quantified total numbers of mesencephalic GFP+ cells, quantification of the total number of striatal GFP+ cells does not accurately reflect differences in transgene expression. Again, we quantified the ratio of GFP+ neurons to glia and did not see any differences with age as the vast majority (>98% for all vectors) of GFP+ cells displayed a neuronal phenotype (Supplementary Figure S6; Supplementary Table S1). Due to tissue processing requirements for striatal GFP+ cell quantitation, we were unable to perform direct protein quantification in the striatum. Therefore, to capture potential differences in levels of GFP expression within cells of the striatum, we quantified...
Using rAAV2/2 displayed an appreciable decrease in GFP mRNA in the aged as compared to young adult rat striatum (Supplementary Figure S7a). These results suggest, at least for rAAV2/2, that age-related deficiencies in GFP protein expression are related to an age-related decrease in GFP mRNA levels.\(^{26,34}\)

Astrocytes display limited tropism for viral particles in the young adult and aged rat striatum. Previous studies report a doubling of astrocytes in the striatum in aged as compared to young adult rats.\(^{35}\) We investigated the possibility that an increased astrocyte-to-neuron ratio impacted striatal neuron transduction efficiency in the aged brain due to astrocytes sequestering viral particles; a phenomenon that would not have been detected simply by looking at GFP expression since the activity of the C\(\beta\)A promoter is highly limited in astrocytes. We used a novel combination of RNAscope in situ hybridization for the viral C\(\beta\)A promoter\(^{35}\) and immunohistochemistry for astrocytes (S100 calcium-binding protein B, S100B) or neurons (Neuronal Nuclei, Neu-N) to visualize the cellular location of viral particles in the transduced zone in the

**Evaluation of GFP mRNA expression following intrastriatal injection.** RNAscope in situ hybridization was used to detect levels of GFP mRNA in striatal tissue one month after intrastriatal viral vector injection. Qualitative analyses failed to reveal any striking differences between young adult and aged rats in levels of GFP mRNA following intrastriatal injection with rAAV2/5, rAAV2/9 or LV (Supplementary Figure S7). However, striatal sections transduced using rAAV2/2 displayed an appreciable decrease in GFP mRNA in the aged as compared to young adult rat striatum (Supplementary Figure S7a). These results suggest, at least for rAAV2/2, that age-related deficiencies in GFP protein expression are related to an age-related decrease in GFP mRNA levels.\(^{26,34}\)

\(\text{P} \leq 0.05\) was observed between ages with rAAV2/2 GFP (\(\text{P} = 0.332\); Figure 4c), rAAV2/9 GFP (\(\text{P} = 0.147\); Figure 4f), or LV GFP (\(\text{P} = 0.758\); Figure 4i). Taken together, these results suggest that an age-related reduction in striatonigral transgene expression is difficult to detect at the level of the striatum following intrastriatal injection.

Figure 2  Quantitation of GFP-positive cells after intranigral injection does not consistently reveal age-related nigrostriatal transgene expression deficiencies. (a,d,g,j) Representative image and quantitation of total GFP+ cells in the midbrain of young adult (Young) and aged (Aged) rats following rAAV2/2, rAAV2/9, rAAV2/5, and LV GFP transduction, respectively. Scale bars = 1,000 \(\mu\)m. No significant differences (\(\text{P} > 0.05\)) were seen between young adult and aged rats in total GFP+ cells with (a) rAAV2/2 (\(n = 5/\text{age}\)), (g) rAAV2/5 (\(n = 13\) young, 5 aged), and (j) LV (\(n = 6\) young, 4 aged), but aged (\(n = 9\)) rats had significantly more GFP+ cells than young adult (\(n = 8\)) rats following (d) rAAV2/9 GFP transduction (*\(\text{P} < 0.05\)). (b,e,h,k) GFP expression within THir SNpc neurons in young adult and aged rats following rAAV2/2, rAAV2/9, rAAV2/5, and LV GFP transduction, respectively. Scale bars = 1,000 \(\mu\)m. (c,f,i,l) Quantitation of GFP+ cells colocalizing with TH+ cells in the SNpc following rAAV2/2, rAAV2/9, rAAV2/5, and LV GFP injection, respectively. Aged rats had significantly fewer (*\(\text{P} < 0.05\)) GFP+/TH+ cells than young adult rats following (e) rAAV2/2 and (l) LV injection (\(n = 4/\text{age/vector}\)). No significant differences (\(\text{P} > 0.05\)) were observed in the number of GFP+/TH+ cells in the SNpc between ages for (f) rAAV2/9 (\(n = 4/\text{age}\)) and (i) rAAV2/5 (\(n = 4\) young, 3 aged). Values are expressed as the percent of the young cell counts ± SEM for each group. GFP, green fluorescent protein; GFP+, GFP immunoreactive; LV, lentivirus; TH+, tyrosine hydroxylase immunoreactive; rAAV, recombinant adeno-associated virus; SEM, standard error of the mean.

---

NK Polinski et al.  Reduced transgene expression in aged striatum and substantia nigra.

Official journal of the American Society of Gene & Cell Therapy  Molecular Therapy — Methods & Clinical Development (2016) 16082

---
Reduced transgene expression in aged striatum and substantia nigra
NK Polinski et al.

Molecular Therapy — Methods & Clinical Development (2016) 16082 Official journal of the American Society of Gene & Cell Therapy

striatum. Despite previous evidence suggesting an increase in the population of astrocytes in the striatum with aging,36 no qualitative increase in S100B astrocytes was observed in the aged compared to the young striatum. Further, in both the young adult and aged brain, for all vector constructs, viral genomes overwhelmingly colocalized with NeuN-immunoreactive neurons (Figure 5a–c and Figure 5g–i), indicating their presence within neurons, corresponding with our GFP-expression data (Supplementary Figures S4 and S6). Viral genomes within neurons appeared as numerous, dense Cβ puncta. In contrast, viral genomes were rarely observed in astrocytes (Figure 5d–f and Figure 5j–l) and if observed, most often appeared as puncta representative of single viral genomes (Figure 5f,l). These results indicate that astrocytes in the aged striatum do not impact transduction efficiency via sequestration of viral particles. Further, although use of astrocyte-specific promoters such as the GFAP promoter (rather than the CβA promoter) can limit gene expression to astrocytes,37 our results suggest that rAAV2/2, rAAV2/5, rAAV2/9 and LV have limited tropism for astrocytes in the brain compared to neurons.

Experiment 3. Comparisons between rAAV pseudotype transgene expression in young adult and aged rats

rAAV2/9 delivers the most exogenous GFP protein to the nigrostriatal system of both young adult and aged rats. Nigrostriatal transgene expression following injection into the SNpc was assessed by quantifying GFP protein levels in the ipsilateral striatum (Supplementary Figure S1). Comparisons were made between all

Figure 3 Viral vector-mediated expression of GFP is reduced in the aged striatonigral system with rAAV2/2, rAAV2/5, and rAAV2/9, but not LV. Representative Western blot and quantitation of GFP immunodetection in substantia nigra pars reticulata (SNpr) samples of young adult (Young) and aged (Aged) rats one month post-injection with (a) rAAV2/2 GFP; (b) rAAV2/9 GFP; (c) rAAV2/5 GFP; or (d) LV GFP. (a) Aged (n = 5) rats displayed significantly less GFP than young adult (n = 4) rats following rAAV2/2 GFP transduction (***P \leq 0.001). (b) Aged (n = 6) rats display decreased GFP levels in the SNpr as compared to young adult (n = 5) rats following rAAV2/9 GFP transduction (***P \leq 0.001). (c) Aged (n = 6) rats expressed significantly less GFP than young adult (n = 6) rats following rAAV2/5 GFP transduction (*P \leq 0.05). (d) Aged (n = 4) and young adult (n = 6) rats expressed equivalent GFP in the SNpr following LV GFP transduction (P > 0.05). Values are expressed as the percent of the young mean optical density scores, with GFP signal normalized to tubulin controls ± SEM for each group. GFP, green fluorescent protein; LV, lentivirus; rAAV, recombinant adeno-associated virus; SEM, standard error of the mean.
three rAAV pseudotypes injected with near-identical vector titers (rAAV2/2 = 1.9 × 10^{12} genomes/ml, rAAV2/5 = 2.0 × 10^{12} genomes/ml, and rAAV2/9 GFP at 2.0 × 10^{12} genomes/ml). LV was excluded from between-vector comparisons due to marked titer and transduction process differences. Injection of rAAV2/9 GFP into the SNpc resulted in significantly higher levels of GFP protein in the striatum of young adult (F(2,5) = 1232.34, P < 0.001; rAAV2/2 versus rAAV2/9, P < 0.001; rAAV2/5 versus rAAV2/9, P < 0.001) and aged brains (F(2,5) = 74.79, P = 0.003; rAAV2/2 versus rAAV2/9, P = 0.005; rAAV2/5 versus rAAV2/9, P = 0.005) (Figure 6a). rAAV2/5 nigrostriatal transduction efficiency was comparable with rAAV2/2 in aged rats, and although higher than rAAV2/2 in young rats, this did not reach statistical significance (P > 0.05). These results demonstrate that rAAV2/9 injections into both the young and aged SNpc result in the most efficient delivery of exogenous protein to nigrostriatal circuitry.

rAAV2/5 and rAAV2/9 transduce the greatest numbers of mesencephalic neurons in both young adult and aged rats. Following injection into the SNpc, comparisons were made between vectors in the number of total GFP+ cells throughout the midbrain (Figure 6b). Statistical differences were observed between vectors in both the young adult (F(2,15) = 5.23, P = 0.019) and the aged (F(2,12) = 11.80, P = 0.001) rats. Specifically, in the young adult midbrain, rAAV2/2 injection into the SNpc resulted in the lowest number of midbrain GFP+ cells with significantly fewer than rAAV2/9 (P = 0.018) but not rAAV2/5 (P = 0.165) (Figure 6b). In aged rats, a similar pattern was observed in which rAAV2/2 injections into the SNpc resulted in the fewest number of GFP+ cells in the mesencephalon, with significantly fewer than rAAV2/5 (P = 0.008) and rAAV2/9 (P = 0.003). These results indicate that rAAV2/9 and rAAV2/5 yield the greatest number of transduced cells in the mesencephalon following SNpc injection, regardless of age.

rAAV2/5 and rAAV2/9 transduce the greatest numbers of TH+ SNpc neurons in young adult and aged rats. Statistical differences between vector constructs were also observed when SNpc neurons coexpressing TH and GFP were quantified (young adult, F(2,9) = 5.21, P = 0.031; aged, F(2,8) = 9.88, P = 0.007) (Figure 6c). In young adult rats, injection of rAAV2/5 into the SNpc resulted in the highest number of GFP+/TH+ SNpc neurons, with rAAV2/9 displaying significantly more GFP+/TH+ cells than rAAV2/2 (P = 0.035), but not rAAV2/9 (P = 0.172) (Figure 6c). In aged rats, the pattern was similar in that both rAAV2/5- and rAAV2/9-injected rats possessed significantly more GFP+/TH+ SNpc neurons than rAAV2/2 (rAAV2/5 versus rAAV2/2, P = 0.045; rAAV2/9 versus rAAV2/2, P = 0.008) (Figure 6c). Collectively, our results demonstrate that injections of both rAAV2/5 and rAAV2/9 result in the greatest numbers of transduced nigrostriatal dopamine neurons in young adult and aged rats compared to rAAV2/2. However, rAAV2/9 delivers the highest levels of GFP transgene to the young adult and aged nigrostriatal system by delivering the greatest levels of GFP transgene (=35–63× greater) (Figure 6a).

rAAV2/9 delivers the most exogenous GFP protein to the striatonigral system of both young adult and aged rats. Comparisons in striatonigral transgene expression were made following intrastral injection of rAAV2/2 and rAAV2/9 in young adult and aged rats. As previously described, transgene expression in the striatonigral system was
assessed by quantifying GFP levels in the SNpr following injection into the striatum (Supplementary Figures S1 and S2). rAAV2/5 was excluded from the GFP SNpr protein analyses due to lack of sample. The titers for the two rAAV pseudotypes injected into the striatum were relatively identical (rAAV2/2 = 1.9 × 10^{12} genomes/ml and rAAV2/9 GFP = 2.0 × 10^{12} genomes/ml). Similar to overall transduction efficiency measures in the nigrostriatal system, GFP levels in the SNpr resulting from intrastriatal rAAV2/9 injection were significantly greater than SNpr GFP levels following intrastriatal rAAV2/2 injection in both the young adult (P = 0.003) and aged (P < 0.001) rat (Figure 7a). These results demonstrate that although advanced age negatively impacts the striatonigral transgene expression via rAAV2/9, rAAV2/9 remains the vector construct most capable of delivering high levels of exogenous protein to the striatonigral circuitry of both young adult and aged rats.

rAAV2/9 transduces the greatest number of striatal cells in both young adult and aged rats. Total numbers of GFP+ cells in the striatum were quantified after intrastriatal vector injection into young adult and aged rats and compared between vectors within each age group.

Multiple significant differences were observed in the young adult striatum using this outcome measure (F_{2,10} = 69.89, P < 0.001) (Figure 7b). rAAV2/9 resulted in more GFP+ cells than rAAV2/2 (P < 0.001) and rAAV2/5 (P < 0.001). In addition, rAAV2/5 resulted in more GFP+ cells than rAAV2/2 (P = 0.006). A similar pattern was observed in the aged brain (F_{2,10} = 12.54, P = 0.002) (Figure 7b) with rAAV2/9 injection resulting in significantly more GFP+ cells in the striatum compared to all other vectors (rAAV2/9 versus rAAV2/5, P = 0.025; rAAV2/9 versus rAAV2/2, P = 0.002). However, unlike results in young adults rats where intrastriatal injection of rAAV2/5 yielded more GFP+ neurons compared to rAAV2/2, in the aged brain intrastriatal rAAV2/5 resulted in statistically equivalent numbers as rAAV2/2 (P > 0.05). These results indicate that intrastriatal injection of rAAV2/9 yields the highest number of transduced cells in the striatum, regardless of age.

Following intrastriatal vector injections, GFP intensity in the striatum parallels GFP levels in the SNpr. Due to tissue processing requirements for striatal GFP+ cell quantification, we were unable to perform direct protein quantification in the striatum. To approximate

![Figure 4](image-url)
Differences were observed in the size of the GFP+ transduction area in the striatum for each vector at both ages (Figure 7d). Significant vectors, we measured the area of the GFP immunoreactivity in the striatum. To compare the area of striatal transduction between the injection site can be a critical characteristic informing vector degree of vector spread away from rAAV2/9 results in the largest area of striatal transduction in both aged rats, however this intensity was not significantly higher than P = 0.005; aged, P = 0.001) (Figure 7d). Furthermore, no significant differences (P > 0.05) were observed in the transduction area of any viral construct for aged as compared to young adult rats (Figure 7d), supporting previous reports that an age-dependent diffusivity barrier is not the mechanism of the decreased transduction efficiency. Collectively, our results using different vector constructs injected to the striatum indicate that despite reductions in transgene expression with advanced age, rAAV2/9 provides the greatest exogenous protein delivery and transduces the most striatal neurons compared to rAAV2/5 and rAAV2/2.

**DISCUSSION**

In the present study, we systematically investigated the generalizability of previous findings that advanced age appears to present a barrier to efficient viral vector transduction in the rat brain. To this end, we injected rAAV2/2, rAAV2/5, rAAV2/9, and LV expressing GFP into the SNpc to transduce the nigrostriatal system or into the striatum to transduce the striatonigral system. We prioritized measurements of GFP protein in anterograde structures as the primary readout of transgene expression based on the ability of this outcome measure to provide a simultaneous readout of protein delivery and pathway specificity. We also used multiple additional outcome measures to quantify transduced neurons, measure GFP mRNA, and evaluate vector spread. In general, we observe a decrease in exogenous transgene expression following injection of most of the viral vectors tested in the nigrostriatal and striatonigral systems. Importantly, age-related decreases in GFP expression are not identical when targeting nigrostriatal versus striatonigral pathways. Specifically, following injections into the aged SNpc, transgene expression mediated by rAAV2/2, rAAV2/5, and LV is significantly compromised whereas rAAV2/9-mediated transduction is not negatively impacted by advanced age (Figure 1). Transgene expression in the aged striatonigral system is similarly compromised for all the rAAV pseudotypes; however, GFP expression mediated by LV is not deficient with age (Figure 3). For both neural pathways, however, rAAV2/9 emerged as the viral construct capable of delivering the most exogenous GFP protein to both young adult and aged rats, despite the decrease of transgene expression observed in the striatonigral system (Figures 6 and 7). For transduction of the greatest number of nigrostriatal dopamine neurons, both rAAV2/5 and rAAV2/9 were superior to the other vector constructs, regardless of age. These results provide evidence that age-related decreases in transgene expression are specific to viral construct and cannot be generalized across brain structures.

Another important finding of our study is that age-related transgene decreases (reduced GFP expression) in both neural pathways were not appreciable using quantitation of GFP+ cells. Unbiased stereological counts of GFP+ cells at the injection site did not reveal significant deficits in aged rats following SNpc or striatal injections, and differences in GFP protein delivery between vector constructs were not always detectable using GFP+ cell counts. This could be the result of multiple factors. For instance, the binary nature of cell counts (GFP+ “yes” or “no”) could conceal differences in per-cell
multiplicity of infection (MOI) that could account for the observed decrease in GFP protein expression with advanced age. This possibility is corroborated by a previous report describing decreased immunoreactivity in individually-transduced aged neurons following rAAV2/2 transduction of the aged and young adult rat septum.25 Further, injections into the SNpc result in the transduction of both nigral dopamine neurons as well as other nondopaminergic neurons in the SN and surrounding ventral mesencephalon. As a result, counts of GFP+ cells in the mesencephalon could provide an inaccurate picture of the relative numbers of GFP+/TH+ SNpc neurons. Quantitation of GFP+ cells is the most common outcome measure used to report transduction efficiency.8,22,23,30,31,38,39 Our findings confirm previous reports in which rAAV2/2, rAAV2/5, and rAAV2/9 generally result in the greatest number of GFP+ cells, followed by rAAV2/5 and lastly rAAV2/2.3,14,16 Further, our results mirror those in which counts of GFP+/TH+ nigral neurons are greater following injection of rAAV2/2 into the SNpc compared to rAAV2/2.11 However, despite the fact that both rAAV2/9 and rAAV2/5 resulted in similar numbers of transduced SNpc neurons, this only partially predicted GFP protein expression. These results indicate that caution should be exercised when using counts of GFP+ cells or GFP+/TH+ neurons to assess efficiency of transgene expression.

The mechanism dictating reduced transgene expression in the aged brain is unclear. Previous studies have reported a doubling of astrocytes in the striatum of aged as compared to young adult rats.36 To investigate the possibility that reduced transgene expression in the aged striatum is due to increased numbers of astrocytes sequestering viral genomes from neurons, we analyzed the number of viral particles within neurons vs. astrocytes. We did not observe any appreciable qualitative differences in the number of astrocytes in the young adult versus aged rat striatum. Further, regardless of vector construct, viral genomes were overwhelmingly observed within neurons and rarely observed within astrocytes. Taken together, these results indicate that the mechanism of the age-related decrease in striatal AAV transgene expression is not due to astrocyte sequestration of viral particles.

The fact that age-related decreases in exogenous transgene expression in the brain are not universal eliminates potential ubiquitous age-related impairments such as axonal transport deficits as a possible mechanism. Furthermore, age-related axonal transport deficits are unlikely to be involved due to the fact that untagged GFP is not believed to be actively transported along axons but, rather, freely diffuses through the cell.40 Our present and past data26 demonstrating that vector spread is unaffected by aging also suggest that reduced diffusivity in the aged brain is not a factor. Instead, we suggest that capsid-mediated differences are implicated in the observed transduction deficiencies. We point to the fact that rAAV2/2 and rAAV2/5 transduction is deficient in the aged nigrostriatal system whereas rAAV2/9 is not. The viral genome of these three rAAV pseudotypes is identical, and the sole difference between them is the capsid used—implicating capsid-related steps of transduction in the age-related deficiencies for rAAV.41 One capsid-related step of transduction that could be deficient with age is receptor-mediated endocytosis. Each vector pseudotype uses a distinct set of receptors for endocytosis (main receptors: rAAV2, heparin sulfate proteoglycan42,43; rAAV5, 2,3-linked sialic acid44; rAAV9, N-linked galactose45,46; VSV-G LV, phosphatidylycerine47,48) and a precedence exists for a decrease in some receptors in the aged as compared to young adult brain.49,50 Furthermore, the qualitative and quantitative deficits in GFP mRNA we observed parallel protein deficiencies, further implicating steps of transduction prior to protein synthesis in our observed transduction deficiencies.26,34,41 Additional experiments will be required to determine the cause of the age-related transduction deficiencies in an effort to circumvent deficiencies and improve transduction in the aged brain.

Characterizing the efficiency of transduction between young adult and aged rats is important when using viral vectors as research tools in studies of aging or age-related disease. For instance, previous studies in our lab attempted to overexpress human wildtype alpha-synuclein (α-syn) using rAAV2/5 injected into the young adult and aged rat SNpc in order to investigate mechanisms of α-syn-related toxicity in the aged brain environment.7 Unbiased...
stereological estimates in the SNpc revealed equivalent neuronal loss between young adult and aged rats. Without the additional examination of α-syn protein expression, these results could have been misinterpreted to suggest that aging does not impact α-syn-mediated toxicity. However, measurements of exogenous human wildtype α-syn in the striatum revealed substantially less rAAV2/5-delivered α-syn protein in the aged as compared to young adult rat striatum.1 With this information, our results suggest the opposite conclusion—that aging exacerbates α-syn toxicity. Importantly, any paradigm utilizing viral vector-delivered protein to make comparisons between the aged and young adult brain should verify equivalent expression levels in their neural system of interest.

The striatum is the structure most often targeted in PD gene therapy clinical trials,3,13,16,28 as this approach can be used to simultaneously provide exogenous protein to dopaminergic nigrostriatal terminals and anterogradely deliver protein to the SN via the striatogniral pathway.32,33 In our laboratory, we have successfully used intrastriatal transduction of the young adult rat striatum with a trophic factor (pleiotrophi) to protect the nigrostriatal dopamine system from 6-hydroxydopamine toxicity.51 Our present results suggest that despite the age-related deficiency in transduction observed, intrastratal rAAV2/9 may be optimally suited to deliver the greatest amount of trophic factor to the aged striatogniral system (as well as the aged nigrostriatal system). However, it is important to note that multiple concerns underlie the use of rAAV9, such as an elicitation of an adaptive immune response and subsequent neuronal loss that has been associated with this vector when delivering potentially antigenic proteins.52,53 Furthermore, the ability of rAAV9 to cross the blood–brain barrier and possibly escape the brain after intraparenchymal injection may also be an important consideration.54 It is possible that altering the promoter, transgene, vector backbone, or titer may combat some of these issues and improve the safety profile of the rAAV9 for use in gene therapy for neurodegenerative diseases.53,54

Gene therapy clinical trials for PD use rAAV2/2 or LV for transduction of the aged striatum.3,13,16,28 Our results demonstrate that striatogniral rAAV2/2-mediated transgene expression is markedly reduced with aging and is less efficient compared to rAAV2/5 and rAAV2/9. Additional studies should be conducted to identify the optimal vector construct for safe and efficient transgene delivery to the aged parkinsonian brain. Ideally, studies should be extended to also address whether expression of other transgenes is impacted by aging, especially those encoding biologically-relevant or secretable proteins such as glial cell line-derived neurotrophic factor. The impact of age on viral vector transduction efficiency is an extremely important consideration as efficient transduction will be required for functionally-meaningful gene therapy for age-related neurodegenerative diseases.
**MATERIALS AND METHODS**

**Experimental overview**

Cohorts of Fischer 344 (F344) rats, 10 young adult (3 months old) and 10 aged (20 months old) per cohort, were unilaterally injected with rAAV2/5, rAAV2/2, rAAV2/9, or VSV-G pseudotyped LV (LV) expressing GFP into the SNpc (nigrostriatal transduction) or into the striatum (striatonigral transduction) (Supplementary Figure S1). All cohorts were sacrificed 1 month postinjection. In general, the anagertude structure of the system—stria-tum for nigrostriatal system and SN pars reticulata (SNpr) for striatonigral system—was used for Western blot analysis of GFP protein and the brain region containing the injected structure was used for immunohistochemical staining and in situ hybridization (or qPCR for rAAV2/2 and rAAV2/9 injections in the SNpc). We chose to perform transduced cell quantitation in the injected structure and transgene expression in the anagertude structure protein to allow for the proper quality control of injection placement that is made possible by immunohistochemical examination of transduction area in situ. Outliers were removed if they displayed a misplaced injection or met the criteria for exclusion through the ADAF vector method^16^ and were not included in any outcome measure in this study (see Supplementary Table S2 for detailed information on outlier removal for each cohort).

**Animals**

Male, Fischer 344 rats (National Institute on Aging, Bethesda, MD) 3 months of age (n = 98) and 20 months of age (n = 102) were used in this study. All animals were given food and water ad libitum and housed in 12 hours reverse light–dark cycle conditions in the Van Andel Research Institute vivarium, which is fully Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) approved. All procedures were conducted in accordance with guidelines set by the Institutional Animal Care and Use Committee of Michigan State University.

**Viral vectors**

All rAAV viral vector constructs were purchased from the University of Florida Powell Gene Therapy Center Vector Core (University of Florida, Gainesville, FL). Plasmid and vector production were completed as previously described.56–58 For all vectors, expression of the transgene was driven by the chicken beta actin/cytomegalovirus enhancer (C/CA/CMV) promoter hybrid. For rAAV production, humanized GFP was inserted into an AAV plasmid backbone containing AAV2 inverted terminal repeats and was packaged into AAV5, AAV2, or AAV9 capsids via cotransfection with a plasmid containing rep and cap genes and adeno virus helper functions. Particles were purified using iodixanol gradients followed by column chromatography, and dotblot was used to determine vector titer.59 For LV production, the same GFP expression cassette was inserted into an LV transfer vector and triple transfections were performed into HEK-293 cells with the LV transfer vector and LV helper plasmids and LV was purified from cellular media by ultracentrifugation.39 The vector titers used in this study were the following: rAAV2/2 GFP at 1.9 × 10^11^ vector genomes (vg)/ml, rAAV2/5 GFP 2.0 × 10^11^ vg/ml, rAAV2/9 GFP at 2.0 × 10^11^ vg/ml, LV in the striatum at 2.0 × 10^12^ vg/ml, and LV in the SNpc at 5.0 × 10^12^ vg/ml. Due to the unexpected attrition of many aged rats following the first set of nigral and striatal rAAV2/5 injections, we performed additional vector injections using an additional stock of rAAV2/5 GFP that despite best titer adjustment efforts was slightly lower (1.2 × 10^11^ vg/ml, not 2.0 × 10^11^ vg/ml). Comparisons within vector type between young and aged rats were made in rats injected with the identical titer and comparisons between vector constructs were made only in rats injected with a vector titer between 1.9–2.0 × 10^12^ vg/ml, excluding the rats injected with rAAV2/5 GFP at the 1.2 × 10^12^ vg/ml titer. All surfaces (syringes, pipettes, and microcentrifuge tubes) were coated in SigmaCote (Sigma-Aldrich, St. Louis, MO) prior to coming in contact with the virus to minimize binding of viral particles.60

**Viral vector injections**

All surgical procedures were performed under isofluorane anesthesia (5% in O_2 for induction and 2% in O_2 for maintenance). Rats were placed in a stereotactic frame and a Hamilton syringe fitted with a glass capillary needle (Hamilton Gas Tight syringe 80,000, 26G 2” needle; Hamilton, Reno, NV; coated in SigmaCote) was used for injections. For intranigral injections of GFP-expressing viruses, two 2 µl injections were injected in the left SNpc at coordinates (from dura) AP ~5.3 mm, ML +2.0 mm, DV ~7.2 mm, and AP ~−6.0 mm, ML +2.0 mm, and DV ~−7.2 mm as previously described.60,61 For intrastriatal injections of GFP-expressing viruses, one 2 µl injection was injected in the left striatum at coordinates (from dura) AP +0.0 mm, ML +2.7 mm, DV −4.0 mm in the young adult and adjusted to AP +0.0 mm, ML +3.0 mm, DV −4.0 mm in the aged rat.61 The glass needle was lowered to the site and vector injection began immediately at a rate of 0.5 µl/minute and remained in place after the injection for an additional 5 minutes before retraction.

**Euthanasia and tissue preparation**

All rats were sacrificed 1 month postinjection. Rats were deeply anesthetized (60 mg/kg, pentobarbital, i.p.) and perfused intracardially with 0.9% saline containing 1 ml/10,000 USP heparin, followed by ice cold 0.9% saline. Rat brains were immediately removed and hemisected in the coronal plane at approximately AP ~−2.64 mm. In rats that were injected in the SNpc, rostral tissue was processed for microdissections and caudal tissue was processed for immunohistochemistry. In rats that were injected in the striatum with GFP-expressing viral vectors, rostral tissue was processed for immunohistochemistry, and caudal tissue was processed for microdissections.

**Microdissections of striatum and SNpr**

After brain removal, portions of the brains designated for microdissection were chilled in ice-cold saline for 2 minutes and immediately microdissected (striatal tissue) or flash frozen in 2-methylbutane on dry ice and stored at ~80 °C (SNpc tissue).

**SNpc tissue for RNA analyses (SN-injected GFP vectors)**

Following 2 minutes incubation in ice-cold saline to firm and chill the tissue, 2 mm coronal slabs were blocked from each brain utilizing an aluminum brain blocker (Zivic, Pittsburg, PA). Striatal tissue from both hemispheres was microdissected with a 2 mm tissue punch on a petri dish over ice. Frozen dissected structures were placed in prechilled microcentrifuge tubes and stored at ~80 °C.

**SNpc tissue for RNA analyses (SN-injected rAAV2/2 GFP and rAAV2/9 GFP)**

All surfaces and instruments were cleaned with RNase Away (Invitrogen, Carlsbad, CA) when collecting tissue for RNA analyses. Brains were warmed from −80 °C to −15 °C for 1 hour before use. Brains were mounted onto metal chucks with Tissue-Tek O.C.T. (VWR, Vatavia, IL) before being moved to a −20 °C cryostat for sectioning. Tissue was sectioned until the SNpc became visible. Punches were taken from the rostral face of the brain structures once the structure was definitively apparent to ensure precision. A 2 × 1 mm oval punch of tissue was taken of the SNpc for GFP RNA analyses using a custom punch. Tissue punches were placed in separate prefrrozen RNAse-free microcentrifuge tubes containing TRizol Reagent (Invitrogen, Grand Island, NY) and tissue was homogenized with a pestle before storage. Samples were stored at ~80 °C until time of assay.

**SNpr tissue for protein analyses (STR-injected GFP vectors)**

Brains were transferred from −80 °C to −20 °C before microdissections. Brains were mounted on metal chucks with Tissue-Tek O.C.T. (VWR, Vatavia, IL) before being mounted in the cryostat at −15 °C. Tissue was sectioned until the level of the SNpr and punches were taken from the rostral face of the brain structures once the structure was definitively apparent to ensure precision. While it is possible that GFP expression in the striatum or in the SNpr may reflect some level of retrograde transport from the SNpc and striatal injection sites, respectively, the majority of GFP protein detected in these structures likely represents transgene levels within the nigrostriatal (SNpc injections) and striatonigral circuitry (striatal injections). A 2 × 1 mm oval punch was taken of the region immediately ventral to the SNpc to collect the SNpr using a custom tissue punch. Tissue punches were placed in separate prefrrozen microcentrifuge tubes and stored at −80 °C until time of analysis. SNpr punches were overwhelmingly comprised of tissue from the SNpr with precision of the punch verified by sectioning and immunostaining for tyrosine hydroxylase (Supplementary Figure S2).

**Western blot**

Striatal samples for western blot analyses were homogenized on ice in RIPA Lysis Buffer System (Santa Cruz, Dallas, TX) and SNpr samples for western blot analyses were homogenized on ice in 2% SDS. Total protein...
concentration was determined by the Bradford protein assay. Samples were prepared at 30 ng total protein samples. Western blot protocol was completed as previously described.28 Samples were electrophoresed using SDS-PAGE gels and transferred to Immobilon-FL membranes (Millipore, Bedford, MA). Membranes were incubated in primary GFP antisera (Abcam, Cambridge, MA; rabbit polyclonal IgG, Ab290, 1:1,000) with β-tubulin antisera (Cell Signalling, Danvers, MA; mouse monoclonal IgG, 4466, 1:10,000) overnight. IRDye800 conjugated goat anti-rabbit (LI-COR Biosciences; 926-32211, 1:15,000) and IRDye680 conjugated goat anti-mouse (LI-COR Biosciences, 926-68020, 1:15,000) were used as secondary antibodies. All antibody dilutions were made in LI-COR compatible StartingBlock T20 (TBS) Blocking Buffer (Thermo Scientific, Waltham, MA). Multiplexed signal intensities were imaged with both 700 and 800 nm channels in a single scan with a resolution of 169 μm using the Odyssey infrared image system (LI-COR Biosciences). Reported integrated intensity measurements of GFP expression were normalized according to the corresponding β-tubulin densitymetry measurements as β-tubulin protein levels do not change with age.49 The representative image was produced in Photoshop 7.0 (San Jose, CA).

Immunohistochemistry

The portion of the brains designated for immunohistochemistry were post-fixed in 4% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA) in 0.1M PO4 buffer for seven days. After this period they were transferred to 30% sucrose in 0.1M PO4 buffer until saturated. Brains were frozen on dry ice and tissue was collected as a 1 in 6 series in a 24-well plate. The first five sections were taken at a 40 μm thickness with the remaining well housing two series. Tissue was incubated in the dark. Following primary incubation, tissue was incubated in secondary antisera against mouse IgG (Invitrogen A10037, Alexa Fluor 568 donkey anti-mouse, 1:10,000) for 1 hour at room temperature. Tissue was then blocked in 10% normal goat serum for 1 hour at room temperature until being incubated in the primary antisera against GFAP (Abcam Ab377, mouse anti-GFAP 1:1,000) overnight at 4 °C. Following primary incubation, tissue was incubated in the dark in secondary antisera against mouse IgG (Invitrogen A10037, Alexa Fluor 568 donkey anti-mouse, 1:10,000) for 1 hour at room temperature. Tissue was then blocked in 10% normal goat serum for 1 hour at room temperature before being incubated in the primary antisera against Iba-1 (Wako 019-19741, rabbit anti-Iba-1, 1:1,000) overnight at 4 °C in the dark. Following primary incubation, tissue was incubated in secondary antisera against rabbit IgG (LI-COR 925–68021, goat anti-rabbit IRDye 680LT, 1:500) for 1 hour at room temperature. Sections were mounted on subbed slides, dehydrated via ascending ethanol washes, cleared with xylene, and coverslipped with Cytoseal. Multiplexed signal intensities were imaged with both 700 and 800 nm channels in a single scan with a resolution of 42 μm and depth set to 1.0 μm using the Odyssey infrared image system (LI-COR Biosciences, Lincoln, NE).

GFP/NeuN/glia immunofluorescence

A 1 in 12 series of sections were blocked in 10% normal donkey serum for 1 hour and subsequently transferred to the primary antisera (NeuN: Millipore Ab377, mouse anti-NeuN 1:1,000) to incubate overnight at 4 °C. After primary incubation, tissue was incubated in the dark for 1 hour at room temperature. Tissue was then blocked in 10% normal goat serum for 1 hour at room temperature using the Odyssey infrared image system (LI-COR Biosciences). Images were taken on a Nikon Eclipse 90i microscope with a Nikon DS-R1 camera. Figures were produced in Photoshop 7.0. Brightness, saturation, and sharpness was adjusted only as necessary to best replicate the immunostaining as viewed directly under the microscope.

RNA isolation and cDNA synthesis

RNA was isolated using the Qiashredder (Qiagen, Valencia, CA) and RNeasy Plus Mini kit (Qiagen). The Qiagen protocol for purification of total RNA from animal tissue was used. RNA from tissue was then converted into cDNA using SuperScript VILO Master Mix (Life Technologies). The RNA was assumed to be converted 100% to cDNA.

GFP qPCR

GFP qPCR reactions were carried out with 1x TaqMan Universal Mastermix (ABI, Carlsbad, CA), and a customized TaqMan gene expression assay kit for GFP (ABI). This kit includes 6,000 pmole of the TaqMan MGB-fluorescent probe and 10,000 pmole of each manufactured primer. Forward (R) and reverse (L) primers, as well as the probe (P) sequence were synthesized by ABI. The sequences were as follows: R: AGACCATAGTAAAGACAGACTAGTTT, L: GTCTTGTAGTTCCCGTCATCTTTGA, P: 5′FAM CTCCTGCACATAGCCC MGBNFQ. A total of 20 ng of cDNA was added to each 50 μl reaction mixture which also contained 150 nmol/l forward and 150 nmol/l reverse primers, a 150 nmol/l probe sequence, and TaqMan master mix. qPCR reactions to control for cDNA quantities were run using Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Life Technologies 4352333E) as an endogenous control that is not altered with advanced age in F344 rats. The qPCR reactions were run on an ABI 7500 real-time thermocycler using the following setup: Step 1: Incubation at 50 °C for 2 minutes. Step 2: Incubation at 95 °C for 10 minutes. Step 3: Denaturation at 95 °C for 15 seconds followed by annealing-elongation at 60 °C for 1 minute followed by data collection. Step 3 was cycled 40 times for the qPCR run. Cycle thresholds were chosen during the linear phase of amplification using the AutoC function. All samples were run on the same plate along with a no-template control. Analysis was first carried out using the 2^-ΔΔCT method25 and Relative Expression Software Tool (REST-XL) method.52

RNAseq in situ hybridization for GFP or CBA mRNA

Young adult and aged rats from all eight vector cohorts (rAAV2/2, rAAV2/5, rAAV2/9, and LV injected in the 5Npc or striatum) were used for RNAseq for GFP mRNA. Young adult and aged rats from all striatal injection cohorts
Counts of GFP and TH immunoreactive cells

Tiled images at 10× magnification were taken on the 1:12 series of GFP/NeuN/GFP and GFP/NeuN/ia-1 immunoreactive cells. Tiled images at 10× magnification were taken on the 1:12 series of GFP/NeuN/GFP and GFP/NeuN/ia-1 immunofluorescently stained midbrain or striatal sections of three rats per age per cohort injected in the SNpc with GFP-expressing viral vectors. The rats chosen were representative of the young GFP+ cell counts at the injection site and GFP protein in the anterior tegmentum. Images were taken with a Nikon 90× fluorescence microscope with a Nikon DS-R1i with the exposure constant between images. All GFPir cells that were in focus with a clear nucleus and appeared to be counterstained with NeuN, GFP, and TH were manually counted to determine the total number of GFPir/NeuNir, GFPir/GFAPir, and GFPir/ia-1ir cells. Total numbers of these categories of cells were collected for each rat and then represented as the percent of GFPir cells that were NeuNir, GFPir, or ia-1ir.

Near-infrared signal intensity and striatal transaction area measurements

Comparisons between vectors

For comparisons between vector cohorts in Figures 6 and 7, Western blots were run to include striatal or SNpr samples on one blot to reduce variability. Due to space constraints, only the samples with median GFP protein amounts from the original western blots were run for each group. In addition, only rAAV2/S-infected rats at the 2.0× 1012 genomes/ml were used to normalize titer between AAV pseudotypes for all comparisons between vectors. All data are presented as the raw numbers that were reported as percent of young in earlier figures.

Statistical analyses

All statistical tests were completed using IBM SPSS statistics version (version 22.0, IBM, Armonk, NY). Graphs were created using GraphPad Prism software (version 6, GraphPad, La Jolla, CA). To compare young adult vs. aged rats injected in the same structure with the identical vector construct, independent samples t-tests were used. Results of THir SNpc neuron quantification were analyzed with two-way repeated measures analysis of variance with two treatment factors, age and hemisphere. When appropriate, Bonferroni post hoc analyses were used on analysis of variance tests to determine significance between individual groups. For the qPCR gene expression study, fold changes for the GFP gene were normalized to the GAPDH gene and significance between individual groups using the harmonic mean of the group was determined with multiple comparisons procedures. A two-way ANOVA was run with Bonferroni post hoc tests to determine significance between individual groups using the harmonic mean of the group sizes to account for unequal sample sizes.

CONFLICT OF INTEREST

Authors have no conflicts of interest to disclose.

ACKNOWLEDGMENTS

Special thanks are given to Lauren Congdon, Sho Nakashima, Keri Heydenburg, and Nathan Kuhn for their help with experiments completed in this study. We would also like to thank Jack Lipton for the use of his equipment. This research was supported by the Graduate School of Michigan State University (N.K.P.), Michigan State University Pearl J. Aldrich Endowment in Aging Related Research (C.E.S.), Mercy Health Saint Mary’s (F.P.M.), and the Morris K. Udall Center of Excellence for Parkinson’s Disease Research at Michigan State University NS058830 (T.J.C.). Work was completed in Grand Rapids, Michigan, USA.
REFERENCES

1. O’Connor, DM and Boullis, NM (2015). Gene therapy for neurodegenerative diseases. Trends Mol Med 21: 504–512.
2. Choudhury, SR, Huday, E, Maguire, CA, Sena-Esteves, M, Breakfield, XO and Grandi, P (2016). Viral vectors for therapy of neurologic diseases. Neuropsychopharmacology (epub ahead of print). DOI: 10.1016/j.neuropsychopharm.2016.02.013.
3. Marks Jr, WJ, Bartus, RT, Siffert, J, Davis, CS, Lozano, A, Boullis, N et al. (2010). Gene delivery of AAV2-neurturin for Parkinson’s disease: a double-blind randomized, controlled trial. Lancet 9: 1164–1172.
4. Tusuzynski, MH, Yang, JH, Barba, D, U, HS, Bakay, RA, Pay, MM et al. (2015). Nerve growth factor gene therapy: activation of neuronal responses in Alzheimer disease. JAMA Neurol 72: 1139–1147.
5. Nore, RJ and Almeida, LP (2011). Gene therapy for Parkinson’s and Alzheimer’s diseases: from the bench to clinical trials. Curr Pharm Des 17: 3344–3454.
6. Combis, B, Knyensberg, A and Kanaan, NM (2016). Gene therapy models of Alzheimer’s disease and other demetias. Methods Mol Biol 1382: 339–366.
7. Fischer, DL, Gombash, SE, Kemp, CJ, Manfredsson, FP, Polinski, NK, Duffy, MF et al. (2016). Viral vector-based modeling of neurodegenerative disorders: Parkinson’s disease. Methods Mol Biol 1382: 367–382.
8. Van der Perren, A, Toelen, J, Taymans, JM, and Baekelandt, Y (2012). Using recombinant adeno-associated viral vectors for gene expression in the brain. Neurotherapeutics 5: 47–68.
9. Cummings, JL, Banks, SJ, Gary, RK, Kinney, JW, Lombardo, JM, Walsh, RR et al. (2013). Alzheimer’s disease drug development: translational neuroscience strategies. CNS Spectr 18: 128–138.
10. Stocchi, F and Olanow, CW (2013). Obstacles to the development of a neuroprotective therapy for Parkinson’s disease. Mov Disord 28: 3–7.
11. Maguire, CA, Ramirez, SH, Merkel, SF, Sena-Esteves, M and Breakfield, XO (2014). Gene therapy for the nervous system: challenges and new strategies. Neurotherapeutics 11: 817–839.
12. Emborg, ME, Moirano, J, Raschke, J, Bondarenko, V, Zufferey, R, Peng, S et al. (2009). Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF. Neuropharmacology 5: 303–311.
13. Palfi, S, Gurruchaga, JM, Ralph, GS, Lepetit, H, Lavisse, S, Buttery, PC et al. (2007). Time course of neonatal NGF gene delivery in adult and aged rats. Mol Ther 9: 262–269.
14. Reimsnider, S, Manfredsson, FP, Fiske, JS, Mandel, RJ and Kordower, JH (2009). Gene therapy for neurodegenerative diseases based on NGF delivery: anterograde distribution of AAV2 vectors in the primate basal ganglia. Mol Ther 17: 398–405.
15. Kordower, JH, Emborg, ME, Bloch, J, Ma, SY, Chu, Y, Leventhal, L et al. (2008). Nerve growth factor gene transfer of GDNF in the rat nigrostriatal system. Gene Ther 15: 165ra163.
16. Ryazanov, AG and Nefisky, BS (2002). Protein turnover plays a key role in aging. Mech Ageing Dev 123: 207–213.
17. Grabiniski, TM, Knyensberg, A, Manfredsson, FP and Kanaan, NM (2015). A method for combining RNAScope in situ hybridization with immunohistochemistry in thick free-floating brain sections and primary neuronal cultures. PLoS One 10: e0121200.
18. Yurek, M, Hasselrot, U, Cass, WA, Senesoglou-Laird, O, Padiemegs, L and Cooper, MJ (2015). Age and lesion-induced increases of GDNF transcript expression in brain following intracerebral injections of DNA nanoparticles. Neuroscience 250: 500–512.
19. Meller, M, Stone, IM, Goss, A, Rau, T, Rova, C and Poulsen, DJ (2008). Selective overexpression of excitatory amino acid transporter 2 (EAAT2) in astrocytes enhances neuroprotection from moderate but not severe hypoxia-ischemia. Neuroscience 155: 1204–1211.
20. Cannon, JR, Sew, T, Montero, L, Burton, EA and Greenamyre, JT (2011). Hypomorphic-dependent lentiviral transduction of astrocytes or neurons in the rat substantia nigra. Exp Neurol 228: 41–52.
21. Dodiya, HB, Bjorklund, T, Stansell, J, Mandel, RJ, Kirik, D and Kordower, JH (2010). Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates. Mol Ther 18: 579–587.
22. Lippincott-Schwartz, J, Snapp, E and Kenworthy, A (2001). Studying protein dynamics in living cells. Nat Rev Mol Cell Biol 2: 444–456.
23. Nonnenmacher, M and Weber, T (2012). Intracerebral transport of recombinant adeno-associated virus vectors. Gene Ther 19: 649–658.
24. Sommerford, C and Samulski, RJ (1998). Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 72: 1438–1445.
25. Qi, J, Handa, A, Kirby, M and Brown, KE (2000). The interaction of heparin sulfate and adeno-associated virus 2. Virology 269: 137–147.
26. Walters, RW, Yi, SM, Reshavaye, S, Brown, KE, Welsh, MJ, Chiorini, JA et al. (2001). Binding of adeno-associated virus type 5 to 2,3 linked sialic acid is required for gene transfer. J Biol Chem 276: 20160–20166.
27. Shen, S, Bryant, KD, Brown, SM, Randell, SH and Asokan, A (2011). Terminal N-linked sialic acid depletion: an argument for neurotrophic supplementation. J Neurosci 31: 5653–5573.
28. Collier, TJ, Sortwell, CE and Daley, BF (1999). Diminished viability, growth, and behavioral efficacy of fetal dopamine neuron grafts in aging rats with long-term dopamine depletion: an argument for neurotrophic supplementation. J Neurosci 19: 5563–5573.
29. Collier, TJ, OMalley, J, Ramadran, DJ, Stancati, JA, Sisson, KA, Sortwell, CE et al. (2015). Neuritogen-based aged striatum: robust survival of grafted dopamine neurons in aging rats produces inferior behavioral recovery and evidence of impaired integration. Neurobiol Dis 77: 191–203.
30. Nanou, A and Aazouz, M (2009). Gene therapy for neurodegenerative diseases based on lentiviral vectors. Prog Brain Res 72: 187–200.
31. Reinsminder, S, Manfredsson, FP, Muzyczka, N and Mandel, RJ (2007). Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transection in the rat. Mol Ther 15: 1504–1511.
32. Davidson, BL, Stein, CS, Heth, JA, Martins, I, Kotin, RM, Derksen, TA et al. (2000). Recombinant adenovirus-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci USA 97: 3428–3432.
33. Leone, P, Shera, D, McPhee, SW, Francis, JS, Kolody, EH, Bilaniuk, LT et al. (2012). Long-term follow-up after gene therapy for canavan disease. Sci Transl Med 15: 164ra136.
34. Wu, K, Meyers, CA, Guerra, NK, King, MA and Meyer, EM (2004). The effects of rAAV-mediated NGF gene delivery in adult and aged rats. Mol Ther 9: 262–269.
Reduced transgene expression in aged striatum and substantia nigra
NK Polinski et al.

52. Ciesielska, A, Hadaczek, P, Mittermeyer, G, Zhou, S, Wright, JF, Bankiewicz, KS et al. (2013). Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses. Mol Ther 21: 158–166.
53. Samaranch, L, San Sebastian, W, Kells, AP, Salegio, EA, Heller, G, Bringas, JR et al. (2014). AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction. Mol Ther 22: 329–337.
54. Lowenstein, PR, Yadav, VN, Chockley, P and Castro, M (2014). There must be a way out of here: identifying a safe and efficient combination of promoter, transgene, and vector backbone for gene therapy of neurological disease. Mol Ther 22: 246–247.
55. Leys, C, Ley, C, Klein, O, Bernard, P and Licata, L (2013). Detecting outliers: Do not use standard deviation around the mean, use absolute deviation around the median. J Exp Soc Psychol 49: 764–766.
56. Benskey, MJ and Manfredsson, FP (2016). Lentivirus production and purification. Methods Mol Biol 1382: 107–114.
57. Zolotukhin, S, Byrne, BJ, Mason, E, Zolotukhin, I, Potter, M, Chesnut, K et al. (1999). Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 6: 973–985.
58. Benskey, MJ and Manfredsson, FP (2016). Intraparenchymal stereotaxic delivery of rAAV and special considerations in vector handling. Methods Mol Biol 1382: 199–215.
59. Benskey, MJ, Sandoval, IM and Manfredsson, FP (2016). Continuous collection of adeno-associated virus from producer cell medium significantly increases total viral yield. Hum Gene Ther Methods 27: 32–45.
60. O’Callaghan, JP and Miller, DB (1991). The concentration of glial fibrillary acidic protein increases with age in the mouse and rat brain. Neurobiol Aging 12: 171–174.
61. Schmittgen, TD and Livak, KJ (2008). Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3: 1101–1108.
62. Pfaffl, MW, Horgan, GW and Dempfle, L (2002). Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30: e36.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
© The Author(s) (2016)

Supplementary Information accompanies this paper on the Molecular Therapy—Methods & Clinical Development website (http://www.nature.com/mtm)